Recently, second-generation ABL TKIs dasatinib (Sprycel®) and nilotinib (Tasigna®) have been increasingly used for patients resistant to or intolerant of imatinib therapy, and have been approved for front line use in patients with chronic phase CML [6]. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.